Subsequently, the oncogenic role of GHET1 was suggested in lung cancer [11,12], hepatocellular carcinoma [13,14], breast cancer [15], colorectal cancer [16], esophageal squamous cell carcinoma [17], pancreatic cancer [18], bladder cancer [19], head and neck cancer [20], osteosarcoma [21], and glioma [22]. This evidence concerns the gene GHET1 and central nervous system cancer.